Literature DB >> 6829636

Natural history of hydatidiform mole after primary evacuation.

J R Lurain, J I Brewer, E E Torok, B Halpern.   

Abstract

From 1962 to 1978, 738 patients with hydatidiform mole were referred to the John I. Brewer Trophoblastic Disease Center of Northwestern University for follow-up and human chorionic gonadotropin (hCG) testing after evacuation. There was spontaneous regression of trophoblastic disease in 596 (80.8%) of the 738 patients. Of these 596 patients, regression occurred in 11 (1.8%) by day 10 after evacuation, in 124 (20.8%) between days 11 and 30, in 255 (42.8%) between days 31 and 60, and in 206 (34.6%) between days 61 and 170. Treatment with chemotherapeutic agents was required in 142 (19.2%) of the 738 patients; 125 (16.9%) of these had invasive mole (107 nonmetastatic and 18 metastatic) and 17 (2.3%) had choriocarcinoma (13 nonmetastatic and four metastatic). All 596 patients whose hCG titers declined spontaneously to normal levels have remained well and free of disease. All 142 treated patients experienced permanent remission. Thus, all 738 patients are well and free of disease 4 to 18 years after evacuation of the hydatidiform mole. The follow-up regimen described in this report furnishes information on natural history of molar pregnancies after evacuation and provides an excellent means by which all patients can be safely managed following termination of a hydatidiform mole.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6829636     DOI: 10.1016/0002-9378(83)91202-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  The hydatidiform mole.

Authors:  Jean-Jacques Candelier
Journal:  Cell Adh Migr       Date:  2015-09-30       Impact factor: 3.405

2.  Diagnosis of hydatidiform moles by polymorphic deletion probe fluorescence in situ hybridization.

Authors:  Sarah Chiang; Ladan Fazlollahi; Anhthu Nguyen; Rebecca A Betensky; Drucilla J Roberts; A John Iafrate
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

Review 3.  Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.

Authors:  Natalia Buza; Pei Hui
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

4.  Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

Authors:  A M Gillespie; P C Lorigan; C R Radstone; J C Waterhouse; R E Coleman; B W Hancock
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy.

Authors:  A M Gillespie; S Kumar; B W Hancock
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

6.  Complication of Invasive Molar Pregnancy with Clostridium perfringens Sepsis.

Authors:  Sanmeet Singh; Kunal Angra; Bonnie Davis; Babak Shokrani
Journal:  Case Rep Obstet Gynecol       Date:  2014-02-13

Review 7.  hCG: Biological Functions and Clinical Applications.

Authors:  Chinedu Nwabuobi; Sefa Arlier; Frederick Schatz; Ozlem Guzeloglu-Kayisli; Charles Joseph Lockwood; Umit Ali Kayisli
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

8.  Radiographically occult pulmonary metastases from gestational trophoblastic neoplasia.

Authors:  Tina Hong; Edward Hills; Maria Del Pilar Aguinaga
Journal:  Radiol Case Rep       Date:  2017-02-10

9.  Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia.

Authors:  Jessica D St Laurent; Lawrence H Lin; David M Owen; Izildinha Maestá; Arnold Castaneda; Kathleen T Hasselblatt; Donald P Goldstein; Neil S Horowitz; Ross S Berkowitz; Kevin M Elias
Journal:  Reprod Sci       Date:  2021-06-15       Impact factor: 2.924

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.